Renal Safety of [<sup>177</sup>Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Compromised Baseline Kidney Function

Renal Safety of [<sup>177</sup>Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Compromised Baseline Kidney Function

<i>Background:</i> Radioligand therapy (RLT) targeting prostate-specific membrane antigen (PSMA) is an effective antitumor-treatment in metastatic castration-resistant prostate carcinoma (mCRPC). Concerns of potential nephrotoxicity are based on renal tubular PSMA expression and the resu...

Full description

Bibliographic Details
Main Authors: Florian Rosar, Niklas Kochems, Mark Bartholomä, Stephan Maus, Tobias Stemler, Johannes Linxweiler, Fadi Khreish, Samer Ezziddin
Format: Article
Language:English
Published: MDPI AG 2021-06-01
Series:Cancers
Subjects:
PSMA radioligand therapy
<sup>177</sup>Lu
safety
kidney
renal function
metastatic castration-resistant prostate carcinoma
Online Access:https://www.mdpi.com/2072-6694/13/12/3095

Similar Items

Similar Items